|
Market Closed -
NYSE
16:30:00 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 10.00 USD | 0.00% |
|
-4.31% | -32.20% |
| 07-30 | Daxor Launches Blood Testing Lab in Eastern Kansis | MT |
| 07-30 | Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas | CI |
| Market Cap | 58.38M 50.03M 46.88M 42.82M 80.81M 5.57B 81.61M 553M 215M 2.81B 219M 214M 9.3B | P/E 2026 * |
-47.6x | P/E 2027 * | -333x |
|---|---|---|---|---|---|
| Enterprise Value | 58.38M 50.03M 46.88M 42.82M 80.81M 5.57B 81.61M 553M 215M 2.81B 219M 214M 9.3B | EV / Sales 2026 * |
4.91x | EV / Sales 2027 * | 2.81x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | -2.82% | ||
| Current month | -4.76% | ||
| 1 month | -4.31% | ||
| 6 months | -17.49% | ||
| Current year | -32.20% |
| 1 week | 9.76 | 10.3 | |
| 1 month | 9.76 | 11.15 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2012-12-31 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 2018-09-27 |
John Jefferies
CTO | Chief Tech/Sci/R&D Officer | - | 2024-06-04 |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 1988-12-31 |
| Chairman | 56 | 2017-02-13 | |
Edward Feuer
BRD | Director/Board Member | 70 | 2016-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -4.31% | -7.83% | +2.83% | 58.38M | ||
| +0.34% | +7.36% | +37.24% | +137.44% | 16.76B | ||
| +0.13% | +9.86% | +75.06% | +173.98% | 14.35B | ||
| +0.41% | -0.46% | -9.13% | +30.35% | 9.23B | ||
| +0.83% | +8.79% | +52.08% | +160.70% | 8.28B | ||
| +0.85% | +2.11% | -20.06% | -15.33% | 7.08B | ||
| +2.34% | +8.07% | +19.75% | +49.30% | 7.03B | ||
| +0.25% | +3.53% | +12.66% | +31.78% | 4.97B | ||
| +0.64% | +0.55% | +11.13% | +9.04% | 4.11B | ||
| -0.33% | +0.56% | - | - | 3.95B | ||
| Average | +0.61% | +2.78% | +18.99% | +64.45% | 8.42B | |
| Weighted average by Cap. | +0.57% | +3.74% | +29.96% | +95.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.2M 9.55M 8.73M 16.47M 1.13B 16.63M 113M 43.88M 572M 44.68M 43.71M 1.9B | 20.8M 17.82M 16.7M 15.26M 28.79M 1.98B 29.07M 197M 76.69M 1B 78.1M 76.4M 3.31B |
| Net income | -1.2M -1.03M -964K -880K -1.66M -114M -1.68M -11.37M -4.42M -57.72M -4.51M -4.41M -191M | -200K -171K -161K -147K -277K -19.07M -280K -1.89M -737K -9.62M -751K -735K -31.86M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-25 | US$10.00 | - | 1,082 |
| 26-08-24 | US$0.000000 | -100.00% | 279 |
| 26-08-21 | US$10.00 | - | 2,017 |
| 26-08-20 | US$0.000000 | -100.00% | 27 |
| 26-08-19 | US$10.30 | +0.10% | 202 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.00USD
Average target price
22.50USD
Spread / Average Target
+125.00%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















